Industry Trend Analysis - Pricing Policies Prominent With Higher Patented Drug Demand - OCT 2017


BMI View: Pharmaceutical pricing is a key considera tion for innovative drugmakers and CEE represents a highly varied region in this respect. We note that medicine pricing is highly complex and that an attractive pricing environment does not necessarily reflect an attractive market for innovative product launch. While medicine pricing is a vital consideration, drugmakers must take a holistic approach to the assessment of a market.

The impact of individual countries' pharmaceutical pricing regimes will play a vital role in the assessment of market attractiveness for innovative medicine launches. While just one of many important factors for market assessment, medicine pricing policy will remain a key determinant of revenue generation potential for any new medicines. Here we analyse the pricing regimes of the Central and Eastern European (CEE) markets with reference to BMI's Innovative Pharmaceuticals Risk/Reward Index, a globally comparative tool that quantifies and ranks the potential risks and rewards for innovative drugmakers in a market.

A Varied Region

Pricing Controls More Prominent In EU Markets
CEE: Pharmaceutical Pricing Regime Scores, Q417
Note: Scores out of 100; higher score = lower risk. Source: BMI ' s Innovative Pharmaceuticals Risk/Reward Index.

This article is part of our Western Europe coverage. To access this article subscribe now or sign up for free trial